Literature DB >> 24458010

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

K R Crews1, A Gaedigk2, H M Dunnenberger1, J S Leeder2, T E Klein3, K E Caudle1, C E Haidar1, D D Shen4, J T Callaghan5, S Sadhasivam6, C A Prows7, E D Kharasch8, T C Skaar9.   

Abstract

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24458010      PMCID： PMC3975212          DOI： 10.1038/clpt.2013.254

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  38 in total

1.  Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother.

Authors:  Gideon Koren; James Cairns; David Chitayat; Andrea Gaedigk; Steven J Leeder
Journal:  Lancet       Date:  2006-08-19       Impact factor: 79.321

2.  Codeine, ultrarapid-metabolism genotype, and postoperative death.

Authors:  Catherine Ciszkowski; Parvaz Madadi; Michael S Phillips; Albert E Lauwers; Gideon Koren
Journal:  N Engl J Med       Date:  2009-08-20       Impact factor: 91.245

3.  Codeine and morphine pathway.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

4.  Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability.

Authors:  H L Kaplan; U E Busto; G J Baylon; S W Cheung; S V Otton; G Somer; E M Sellers
Journal:  J Pharmacol Exp Ther       Date:  1997-04       Impact factor: 4.030

5.  Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs.

Authors:  Donna A Volpe; Grainne A McMahon Tobin; R Daniel Mellon; Aspandiar G Katki; Robert J Parker; Thomas Colatsky; Timothy J Kropp; S Leigh Verbois
Journal:  Regul Toxicol Pharmacol       Date:  2011-01-06       Impact factor: 3.271

6.  Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.

Authors:  Bojan Lalovic; Evan Kharasch; Christine Hoffer; Linda Risler; Lee-Yuan Liu-Chen; Danny D Shen
Journal:  Clin Pharmacol Ther       Date:  2006-05       Impact factor: 6.875

7.  Codeine intoxication associated with ultrarapid CYP2D6 metabolism.

Authors:  Yvan Gasche; Youssef Daali; Marc Fathi; Alberto Chiappe; Silvia Cottini; Pierre Dayer; Jules Desmeules
Journal:  N Engl J Med       Date:  2004-12-30       Impact factor: 91.245

8.  Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study.

Authors:  S Willmann; A N Edginton; K Coboeken; G Ahr; J Lippert
Journal:  Clin Pharmacol Ther       Date:  2009-08-26       Impact factor: 6.875

9.  Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.

Authors:  K Eckhardt; S Li; S Ammon; G Schänzle; G Mikus; M Eichelbaum
Journal:  Pain       Date:  1998-05       Impact factor: 6.961

Review 10.  Pharmacogenetics of analgesics: toward the individualization of prescription.

Authors:  Victoria Rollason; Caroline Samer; Valerie Piguet; Pierre Dayer; Jules Desmeules
Journal:  Pharmacogenomics       Date:  2008-07       Impact factor: 2.533
View more
  203 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  The Benefits of Whole-Genome Sequencing Now and in the Future.

Authors:  Alina Khromykh; Benjamin D Solomon
Journal:  Mol Syndromol       Date:  2015-08-13

Review 3.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

4.  Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research.

Authors:  Rachel Huddart; Alison E Fohner; Michelle Whirl-Carrillo; Genevieve L Wojcik; Christopher R Gignoux; Alice B Popejoy; Carlos D Bustamante; Russ B Altman; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2019-01-21       Impact factor: 6.875

Review 5.  Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.

Authors:  Jacob T Brown; Jeffrey R Bishop; Katrin Sangkuhl; Erika L Nurmi; Daniel J Mueller; Jean C Dinh; Andrea Gaedigk; Teri E Klein; Kelly E Caudle; James T McCracken; Jose de Leon; J Steven Leeder
Journal:  Clin Pharmacol Ther       Date:  2019-04-13       Impact factor: 6.875

Review 6.  Perioperative Pain Management and Opioid Stewardship: A Practical Guide.

Authors:  Sara J Hyland; Kara K Brockhaus; William R Vincent; Nicole Z Spence; Michelle M Lucki; Michael J Howkins; Robert K Cleary
Journal:  Healthcare (Basel)       Date:  2021-03-16

7.  Parental Perception of Self-Empowerment in Pediatric Pharmacogenetic Testing: The Reactions of Parents to the Communication of Actual and Hypothetical CYP2D6 Test Results.

Authors:  Sarah Adelsperger; Cynthia A Prows; Melanie F Myers; Cassandra L Perry; Ariel Chandler; Ingrid A Holm; John A Lynch
Journal:  Health Commun       Date:  2016-08-30

8.  How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.

Authors:  Richard J Marrero; Emily J Cicali; Meghan J Arwood; Elizabeth Eddy; David DeRemer; Brian H Ramnaraign; Karen C Daily; Dennie Jones; Kelsey J Cook; Larisa H Cavallari; Kristin Wiisanen Weitzel; Taimour Langaee; Kimberly J Newsom; Petr Starostik; Michael J Clare-Salzer; Julie A Johnson; Thomas J George; Rhonda M Cooper-DeHoff
Journal:  Clin Pharmacol Ther       Date:  2020-07-06       Impact factor: 6.875

Review 9.  PharmVar GeneFocus: CYP2D6.

Authors:  Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-12-09       Impact factor: 6.875

Review 10.  CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.

Authors:  Maxime Meloche; Michael Khazaka; Imad Kassem; Amina Barhdadi; Marie-Pierre Dubé; Simon de Denus
Journal:  Br J Clin Pharmacol       Date:  2020-04-05       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.